177 related articles for article (PubMed ID: 36650267)
21. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
22. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.
Kolb RH; Greer PM; Cao PT; Cowan KH; Yan Y
PLoS One; 2012; 7(11):e50281. PubMed ID: 23166842
[TBL] [Abstract][Full Text] [Related]
23. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
25. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract][Full Text] [Related]
27. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
28. Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.
Álvarez-Quilón A; Terrón-Bautista J; Delgado-Sainz I; Serrano-Benítez A; Romero-Granados R; Martínez-García PM; Jimeno-González S; Bernal-Lozano C; Quintero C; García-Quintanilla L; Cortés-Ledesma F
Nat Commun; 2020 Feb; 11(1):910. PubMed ID: 32060399
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints.
D Arcy N; Gabrielli B
Curr Med Chem; 2017; 24(15):1504-1519. PubMed ID: 27919216
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
31. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
32. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
[TBL] [Abstract][Full Text] [Related]
33. ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Bian K; Muppani NR; Elkhadragy L; Wang W; Zhang C; Chen T; Jung S; Seternes OM; Long W
Oncotarget; 2016 Feb; 7(6):6665-75. PubMed ID: 26701725
[TBL] [Abstract][Full Text] [Related]
34. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
35. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
[TBL] [Abstract][Full Text] [Related]
36. SUMO-Targeted DNA Translocase Rrp2 Protects the Genome from Top2-Induced DNA Damage.
Wei Y; Diao LX; Lu S; Wang HT; Suo F; Dong MQ; Du LL
Mol Cell; 2017 Jun; 66(5):581-596.e6. PubMed ID: 28552615
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
38. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
39. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.
Gómez-Herreros F; Romero-Granados R; Zeng Z; Alvarez-Quilón A; Quintero C; Ju L; Umans L; Vermeire L; Huylebroeck D; Caldecott KW; Cortés-Ledesma F
PLoS Genet; 2013; 9(3):e1003226. PubMed ID: 23505375
[TBL] [Abstract][Full Text] [Related]
40. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
